Zimmer Biomet Holdings Stock Debt To Equity
| ZBH Stock | USD 92.75 1.53 1.62% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Zimmer Biomet's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.50 | 0.66 |
Zimmer | Debt To Equity | Build AI portfolio with Zimmer Stock |
Zimmer Biomet Holdings Company Debt To Equity Analysis
Zimmer Biomet's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Zimmer Biomet Debt To Equity | 0.48 % |
Most of Zimmer Biomet's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zimmer Biomet Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zimmer Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Zimmer Biomet is extremely important. It helps to project a fair market value of Zimmer Stock properly, considering its historical fundamentals such as Debt To Equity. Since Zimmer Biomet's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zimmer Biomet's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zimmer Biomet's interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Zimmer Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Zimmer Biomet Holdings has a Debt To Equity of 0.481%. This is 99.1% lower than that of the Health Care Equipment & Supplies sector and 98.8% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.01% higher than that of the company.
Zimmer Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zimmer Biomet's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zimmer Biomet could also be used in its relative valuation, which is a method of valuing Zimmer Biomet by comparing valuation metrics of similar companies.Zimmer Biomet is currently under evaluation in debt to equity category among its peers.
Zimmer Biomet ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zimmer Biomet's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zimmer Biomet's managers, analysts, and investors.Environmental | Governance | Social |
Zimmer Fundamentals
| Return On Equity | 0.0642 | ||||
| Return On Asset | 0.0433 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 25.5 B | ||||
| Shares Outstanding | 198.18 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 99.90 % | ||||
| Number Of Shares Shorted | 7.55 M | ||||
| Price To Earning | 77.41 X | ||||
| Price To Book | 1.46 X | ||||
| Price To Sales | 2.29 X | ||||
| Revenue | 7.68 B | ||||
| Gross Profit | 5.74 B | ||||
| EBITDA | 2.25 B | ||||
| Net Income | 905.2 M | ||||
| Cash And Equivalents | 525.5 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 6.2 B | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 64.36 X | ||||
| Cash Flow From Operations | 1.5 B | ||||
| Short Ratio | 3.49 X | ||||
| Earnings Per Share | 4.03 X | ||||
| Price To Earnings To Growth | 1.03 X | ||||
| Target Price | 102.92 | ||||
| Number Of Employees | 17 K | ||||
| Beta | 0.61 | ||||
| Market Capitalization | 18.38 B | ||||
| Total Asset | 21.37 B | ||||
| Retained Earnings | 11.1 B | ||||
| Working Capital | 2.22 B | ||||
| Current Asset | 5.85 B | ||||
| Current Liabilities | 1.62 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.75 % | ||||
| Net Asset | 21.37 B | ||||
| Last Dividend Paid | 0.96 |
About Zimmer Biomet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zimmer Biomet Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zimmer Biomet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zimmer Biomet Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| PRNEX | T Rowe Price | |
| RPBAX | T Rowe Price | |
| PRDGX | T Rowe Price | |
| PRFDX | T Rowe Price | |
| RPBAX | T Rowe Price |
Check out Zimmer Biomet Piotroski F Score and Zimmer Biomet Altman Z Score analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Dividend Share 0.96 | Earnings Share 4.03 | Revenue Per Share | Quarterly Revenue Growth 0.097 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.